Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A review of anti-inflammatory agents for symptoms of schizophrenia.

Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL.

J Psychopharmacol. 2013 Apr;27(4):337-42. doi: 10.1177/0269881112467089. Epub 2012 Nov 13. Review.

2.

Drug repurposing and emerging adjunctive treatments for schizophrenia.

Bumb JM, Enning F, Leweke FM.

Expert Opin Pharmacother. 2015 May;16(7):1049-67. doi: 10.1517/14656566.2015.1032248. Epub 2015 Apr 12. Review.

PMID:
25866122
3.

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.

Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS.

Schizophr Bull. 2014 Jan;40(1):181-91. doi: 10.1093/schbul/sbt139. Epub 2013 Oct 8.

4.

Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas.

Torrey EF, Davis JM.

Clin Schizophr Relat Psychoses. 2012 Jan;5(4):208-216. doi: 10.3371/CSRP.5.4.5. Review.

PMID:
22182458
5.

The question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs.

Arolt V, Ambrée O.

Mod Trends Pharmacopsychiatry. 2013;28:100-16. doi: 10.1159/000343972. Epub 2013 Feb 27. Review.

PMID:
25224894
6.

Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.

Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, Oliveira J, Le Guen E, Marlinge E, Tamouza R, Leboyer M.

Acta Psychiatr Scand. 2014 Mar;129(3):163-79. doi: 10.1111/acps.12211. Epub 2013 Nov 11. Review.

PMID:
24215721
7.

The Promise and Limitations of Anti-Inflammatory Agents for the Treatment of Major Depressive Disorder.

Raison CL.

Curr Top Behav Neurosci. 2017;31:287-302. doi: 10.1007/7854_2016_26. Review.

PMID:
27278642
8.

Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin.

El-Sharkawy H, Aboelsaad N, Eliwa M, Darweesh M, Alshahat M, Kantarci A, Hasturk H, Van Dyke TE.

J Periodontol. 2010 Nov;81(11):1635-43. doi: 10.1902/jop.2010.090628. Epub 2010 Jun 23.

PMID:
20572767
9.

Clinical potential of minocycline for schizophrenia.

Miyaoka T.

CNS Neurol Disord Drug Targets. 2008 Oct;7(4):376-81. Review.

PMID:
18991666
10.

Omega-3 fatty acids and schizophrenia: evidences and recommendations.

Marano G, Traversi G, Nannarelli C, Mazza S, Mazza M.

Clin Ter. 2013;164(6):e529-37. doi: 10.7417/CT.2013.1651. Review.

PMID:
24424237
11.

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.

Jaturapatporn D, Isaac MG, McCleery J, Tabet N.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006378. doi: 10.1002/14651858.CD006378.pub2. Review.

PMID:
22336816
12.

Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease.

Yates CM, Calder PC, Ed Rainger G.

Pharmacol Ther. 2014 Mar;141(3):272-82. doi: 10.1016/j.pharmthera.2013.10.010. Epub 2013 Nov 4. Review.

PMID:
24201219
13.

[Antiinflammatory therapy in ostheoarthritis including omega 3 and omega 6 fatty acids].

Dzielska-Olczak M, Nowak JZ.

Pol Merkur Lekarski. 2012 May;32(191):329-34. Review. Polish.

PMID:
22779342
14.

Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials.

Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A.

Br J Nutr. 2012 Jun;107 Suppl 2:S159-70. doi: 10.1017/S0007114512001559. Review.

PMID:
22591890
15.

Polyunsaturated fatty acid supplementation for schizophrenia.

Joy CB, Mumby-Croft R, Joy LA.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001257. Review.

PMID:
16855961
16.

Minocycline: therapeutic potential in psychiatry.

Dean OM, Data-Franco J, Giorlando F, Berk M.

CNS Drugs. 2012 May 1;26(5):391-401. doi: 10.2165/11632000-000000000-00000. Review.

PMID:
22486246
17.

Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages.

Mansur RB, Zugman A, Asevedo EM, da Cunha GR, Bressan RA, Brietzke E.

Psychiatry Clin Neurosci. 2012 Jun;66(4):247-60. doi: 10.1111/j.1440-1819.2012.02354.x. Review.

18.

Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial.

Silva PS, Sperandio da Silva GM, de Souza AP, Cardoso CS, Fonseca CA, Brito PD, Saraiva RM, Brasil PE, Pinheiro RO, Hasslocher-Moreno AM, Xavier SS, Sousa AS.

Trials. 2013 Nov 11;14:379. doi: 10.1186/1745-6215-14-379.

19.

[Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology].

Devillier P.

Presse Med. 2001 Dec 22-29;30(39-40 Pt 2):70-9. French.

PMID:
11819916
20.

Anti-inflammatory treatment in schizophrenia.

Müller N, Myint AM, Krause D, Weidinger E, Schwarz MJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:146-53. doi: 10.1016/j.pnpbp.2012.11.008. Epub 2012 Nov 23. Review.

PMID:
23178230

Supplemental Content

Support Center